Manuel L Penichet

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Clin Immunol 121:144-58. 2006
  2. pmc Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid)
    Manabu Fujita
    Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Control Release 122:356-63. 2007
  3. ncbi request reprint A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery
    Tsuneaki Asai
    Department of Microbiology, Molecular Genetics and Molecular Biology Institute, University of California Los Angeles, CA 90095, USA
    Biomol Eng 21:145-55. 2005
  4. ncbi request reprint Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors
    Gustavo Helguera
    Department of Microbiology, Immunology and Molecular Genetics and the Molecular Biology Institute, University of California, 405 Hilgard Avenue, Box 148906, Los Angeles, CA 90095 1489, USA
    Vaccine 24:304-16. 2006
  5. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
  6. pmc Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor
    Patrick P Ng
    Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Blood 108:2745-54. 2006
  7. ncbi request reprint Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, University of California at Los Angeles, Los Angeles, CA 90095 1782, USA
    Mol Cancer Ther 6:2995-3008. 2007
  8. pmc Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells
    Jose A Rodriguez
    Molecular Biology Institute, David Geff en School of Medicine, University of California, Los Angeles, CA 90095 1782, USA
    Leuk Lymphoma 52:2169-78. 2011
  9. ncbi request reprint Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor
    Jose A Rodriguez
    Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA 90095 1782, USA
    J Control Release 124:35-42. 2007
  10. pmc An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunother 34:500-8. 2011

Research Grants

  1. Universal Vectors for the Therapy of Cancer
    MANUEL PENICHET; Fiscal Year: 2005

Collaborators

Detail Information

Publications38

  1. ncbi request reprint The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Clin Immunol 121:144-58. 2006
    ..We also discuss the efficacy of targeting the TfR using cytotoxic antibodies that inhibit cell growth and/or induce apoptosis in targeted malignant cells...
  2. pmc Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid)
    Manabu Fujita
    Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Control Release 122:356-63. 2007
    ..The results suggest improved efficacy for tandem configuration of antibodies than for single configurations carried by a drug delivery vehicle...
  3. ncbi request reprint A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery
    Tsuneaki Asai
    Department of Microbiology, Molecular Genetics and Molecular Biology Institute, University of California Los Angeles, CA 90095, USA
    Biomol Eng 21:145-55. 2005
    ..These results suggest that when combined with P67-based biotinylation, anti-TfR IgG3-Av could serve as a universal delivery vector for targeted chemotherapy of cancer...
  4. ncbi request reprint Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors
    Gustavo Helguera
    Department of Microbiology, Immunology and Molecular Genetics and the Molecular Biology Institute, University of California, 405 Hilgard Avenue, Box 148906, Los Angeles, CA 90095 1489, USA
    Vaccine 24:304-16. 2006
    ..Our results suggest that this approach will be effective in the prevention and/or treatment of HER2/neu expressing tumors...
  5. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
    ....
  6. pmc Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor
    Patrick P Ng
    Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Blood 108:2745-54. 2006
    ..This report provides insights into the mechanism of cell death induced by anti-TfR Abs such as anti-hTfR IgG3-Av, a molecule that may be useful in the treatment of B-cell malignancies such as multiple myeloma...
  7. ncbi request reprint Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, University of California at Los Angeles, Los Angeles, CA 90095 1782, USA
    Mol Cancer Ther 6:2995-3008. 2007
    ..These results suggest that anti-hTfR IgG3-Av has great potential as a therapeutic agent for a wide range of applications due to its intrinsic cytotoxic activity plus its ability to deliver biotinylated molecules into cancer cells...
  8. pmc Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells
    Jose A Rodriguez
    Molecular Biology Institute, David Geff en School of Medicine, University of California, Los Angeles, CA 90095 1782, USA
    Leuk Lymphoma 52:2169-78. 2011
    ..These findings are expected to facilitate the rational design and clinical use of therapeutic agents targeting iron import via TfR1 in hematopoietic malignancies...
  9. ncbi request reprint Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor
    Jose A Rodriguez
    Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA 90095 1782, USA
    J Control Release 124:35-42. 2007
    ..Our results better define the properties of anti-hTfR IgG3-Av and pave the way for the rational design of future in vitro and in vivo studies for the treatment of human malignancies...
  10. pmc An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunother 34:500-8. 2011
    ..Our results suggest that ch128.1Av and ch128.1 may be effective in the therapy of human multiple myeloma and potentially other hematopoietic malignancies...
  11. pmc Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer
    Hui Ding
    Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, USA
    J Control Release 171:322-9. 2013
    ..The present Polycefin(TM) variant may be a promising agent for treating HER2/neu expressing tumors and demonstrates the versatility of the Polycefin(TM) nanobioconjugate platform. ..
  12. pmc A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
    Tracy R Daniels-Wells
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    BMC Cancer 13:195. 2013
    ..47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa...
  13. pmc Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1
    Tracy R Daniels-Wells
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Toxicol In Vitro 27:220-31. 2013
    ..1Av/b-SO6 is not toxic to normal human hematopoietic stem cells suggesting that this critical cell population would be preserved in therapeutic interventions using this immunotoxin...
  14. pmc The transferrin receptor and the targeted delivery of therapeutic agents against cancer
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Biochim Biophys Acta 1820:291-317. 2012
    ..This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death...
  15. ncbi request reprint Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors
    Gustavo Helguera
    Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Box 167817, Los Angeles, CA 90095 1678, USA
    Mol Cancer Ther 5:1029-40. 2006
    ....
  16. ncbi request reprint Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies
    Gustavo Helguera
    Division of Surgical Oncology, David Geffen School of Medicine, University of California at Los Angeles, Box 951782, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 56:1507-12. 2007
    ....
  17. ncbi request reprint The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Clin Immunol 121:159-76. 2006
    ..In this review we summarize the strategies of targeting the TfR in order to deliver therapeutic agents into tumor cells by receptor-mediated endocytosis...
  18. pmc Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, 90095 1782, USA
    Cancer Immunol Immunother 61:991-1003. 2012
    ..In summary, our results suggest that this IgE should be further explored as a potential therapeutic against HER2/neu overexpressing tumors, such as breast and ovarian cancers...
  19. pmc Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells
    Stavroula Baritaki
    Department of Microbiology, Immunology, and Molecular Genetics, Division of Surgical Oncology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 180:6199-210. 2008
    ..The findings also suggest the therapeutic application of subtoxic NPI-0052 concentrations in combination with TRAIL/agonist DR4/DR5 mAbs in the treatment of TRAIL-resistant tumors...
  20. ncbi request reprint Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein
    Jay S Dela Cruz
    Department of Microbiology, Immunology and Molecular Genetics and Molecular Biology Institute, University of California, Box 148906, Los Angeles, CA 90095 1489, USA
    Vaccine 23:4793-803. 2005
    ..These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens...
  21. pmc A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide
    Kouki Morizono
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Gene Med 11:655-63. 2009
    ..We have now developed a more stable conjugation strategy utilizing the interaction between avidin and biotin...
  22. pmc Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity
    Satoshi Inoue
    Department of Neurosurgery and Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 71:1454-64. 2011
    ..Our findings offer a preclinical proof of concept for use of the PMLA nanoplatform for combination cancer therapy...
  23. pmc An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells
    Patrick P Ng
    Department of Microbiology, Immunology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095 1489, USA
    Proc Natl Acad Sci U S A 99:10706-11. 2002
    ..Further development of this technology may lead to effective therapeutics for in vivo eradication of hematological malignancies, and ex vivo purging of cancer cells in autologous transplantation...
  24. ncbi request reprint Antibody-cytokine fusion proteins for the therapy of cancer
    Gustavo Helguera
    Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 109:347-74. 2005
    ..In the present chapter we describe strategies for the construction, expression, and in vitro characterization of antibody-cytokine fusion proteins, with particular emphasis on antibody/IL-2 fusion proteins...
  25. ncbi request reprint Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies
    Jay Soriano Dela Cruz
    Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles UCLA, Los Angeles, CA 90095, USA
    Mol Immunol 43:667-76. 2006
    ....
  26. doi request reprint Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents
    Ramon F Montano
    Department of Microbiology, Immunology and Molecular Genetics, and the Molecular Biology Institute, University of California, Los Angeles, CA, USA
    J Immunol Methods 340:1-10. 2009
    ..This approach might also be used to develop reagents for which cell surface antigen binding and agglutination or aggregation is required...
  27. pmc Antibody-cytokine fusion proteins: applications in cancer therapy
    Elizabeth Ortiz-Sánchez
    University of California, Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Expert Opin Biol Ther 8:609-32. 2008
    ..These molecules have the capacity to enhance the tumoricidal activity of the antibodies and/or activate a secondary antitumor immune response...
  28. pmc Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1
    Lai Sum Leoh
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Mol Immunol 67:407-15. 2015
    ..Our study provides insights into the effector functions of human IgG3 in the context of an antibody targeting TfR1. ..
  29. pmc Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter
    Lai Sum Leoh
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    J Gene Med 16:11-27. 2014
    ..Targeting occurs through the use of ch128.1Av or its parental antibody without avidin (ch128.1) and through transcriptional regulation using an immunoglobulin promoter...
  30. pmc Animal models for IgE-meditated cancer immunotherapy
    Tracy R Daniels
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 54 140, Box 951782, Los Angeles, CA 90095, USA
    Cancer Immunol Immunother 61:1535-46. 2012
    ..This article describes the advantages and disadvantages of these models and their use in evaluating the in vivo properties of IgE antibodies for cancer therapy...
  31. doi request reprint Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry
    Gustavo Helguera
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Immunol Methods 368:54-63. 2011
    ....
  32. pmc Targeting aurora kinases as therapy in multiple myeloma
    Yijiang Shi
    Division of Hematology, Veterans Administration West Los Angeles UCLA Medical School and Jonsson Cancer Center, University of California Los Angeles, CA, USA
    Blood 109:3915-21. 2007
    ..RHAMM overexpression enhanced sensitivity to apoptosis and RHAMM silencing decreased sensitivity. These results suggest potential for aurora kinase inhibitors in MM especially in patients in whom RHAMM is overexpressed...
  33. pmc Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7
    Daniel P Widney
    Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 8:e72414. 2013
    ..This mouse model may be useful for future studies on the interactions of the innate immune system and AIDS-BL tumor cells, as well as for the assessment of potential tumor biomarkers for this disease. ..
  34. ncbi request reprint Myeloma expression systems
    Esther M Yoo
    Department of Microbiology, Immunology and Molecular Genetics and the Molecular Biology Institute, University of California Los Angeles, 611 S Charles Young Drive, Los Angeles, CA 90095, USA
    J Immunol Methods 261:1-20. 2002
    ..In addition, novel proteins in which antibodies are fused to non-immunoglobulin sequences as well as secretory IgA have been produced in myeloma cells...
  35. pmc Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks
    Jose A Rodriguez
    Department of Surgery, Division of Surgical Oncology, Molecular Biology Institute, The David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 106:19322-7. 2009
    ..Our study demonstrates that millisecond differential interference-contrast microscopy can be a useful tool for uncovering important short-time features of microorganism locomotion...
  36. pmc IgE immunotherapy against cancer
    Lai Sum Leoh
    Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 54 140, Box 951782, Los Angeles, CA, 90095 1782, USA
    Curr Top Microbiol Immunol 388:109-49. 2015
    ..Further studies on the anticancer efficacy and safety profile of these IgE-based approaches are warranted in preparation for translation toward clinical application. ..
  37. ncbi request reprint Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice
    Jay S Dela Cruz
    Department of Microbiology, The Molecular Biology Institute, University of California, 405 Hilgard Avenue, Los Angeles 90095 1489, USA
    Vaccine 21:1317-26. 2003
    ..Taken together these results suggest that vaccines including ECD(HER2) and Ab-cytokine fusion proteins may be used to elicit both humoral and cell-mediated responses against HER2/neu...
  38. ncbi request reprint Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
    Hyun Mi Cho
    Department of Medicine, Hematology Oncology, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center, FL 33136, USA
    Mol Cancer Ther 4:956-67. 2005
    ..Linking of an antiangiogenic protein, such as endostatin, to a targeting antibody represents a promising and versatile approach to antitumor therapy...

Research Grants1

  1. Universal Vectors for the Therapy of Cancer
    MANUEL PENICHET; Fiscal Year: 2005
    ..The training period will also allow me to attend national and international meetings, both expanding my expertise and my network of collaborators and colleagues. ..